Skip to content

13F-HR filed by Opaleye Management Inc.

Opaleye Management Inc. filed this 13F-HR for the quarter ended 2015-03-31, filed 2015-05-15, with 37 holding rows worth $215,386,000.

Accession
0001546927-15-000149
Filed
2015-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2015

A holdings report, 37 entries on the cover page, a total value of $215,386,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $215,386,000 with VALUE read as thousands by filing date, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CHIMERIX INC COM16934W106Stock565,000$21,295,000thousands by filing date
CEMPRA INC15130J109COM500,000$17,155,000thousands by filing date
ARIAD PHARMACEUTICALS INC04033A100COM1,500,000$12,360,000thousands by filing date
RETROPHIN INC761299106COM500,000$11,980,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM140,000$10,392,000thousands by filing date
AMAG PHARMACEUTICALS INC00163U106COM190,000$10,385,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM90,000$8,487,000thousands by filing date
CODEXIS INC192005106COM1,724,000$7,861,000thousands by filing date
GERON CORP374163103COM1,825,000$6,880,000thousands by filing date
Medgenics Inc New58436Q203COM NEW850,000$6,851,000thousands by filing date
ULTRAGENYX PHARMACEUTICAL IN90400D108COM110,000$6,830,000thousands by filing date
SUPERNUS PHARMACEUTICALS868459108COM535,000$6,468,000thousands by filing date
TETRAPHASE PHARMACEUTICALS INC88165N105COMMON STOCK175,000$6,412,000thousands by filing date
INSYS THERAPEUTICS INC45824V209COMMON STOCK110,000$6,394,000thousands by filing date
MIMEDX GROUP INC602496101COM590,000$6,136,000thousands by filing date
FIBROGEN INC31572Q808COM191,338$6,004,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM145,000$5,758,000thousands by filing date
IMPRIMIS PHARMA IMMY45323A201COMMON687,100$5,490,000thousands by filing date
FLAMEL TECHNOLOGIES-SP ADR338488109SPON300,000$5,394,000thousands by filing date
TRILLIUM THERAPEUTICS INC COM NEW89620X506Stock260,000$5,260,000thousands by filing date
OPHTHOTECH CORP683745103COM105,000$4,886,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM255,000$4,460,000thousands by filing date
KITE PHARMA INC49803L109COM76,000$4,384,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW1,754,000$4,104,000thousands by filing date
AXOGEN INC05463X106COM985,900$3,451,000thousands by filing date
CARA THERAPEUTICS INC140755109COM315,000$3,166,000thousands by filing date
ZS PHARMA INC98979G105Common Stock75,000$3,156,000thousands by filing date
Lion Biotechnologies53619R102COM200,000$2,422,000thousands by filing date
Accelerate Diagnostics00430H102COM100,600$2,264,000thousands by filing date
TENAX THERAPEUTICS INC88032L100COM606,200$1,976,000thousands by filing date
EVOKE PHARMA INC30049G104COM245,000$1,727,000thousands by filing date
MACROGENICS INC556099109COM50,000$1,569,000thousands by filing date
BIODELIVERY SCIENCES INTL IN09060J106COM140,500$1,475,000thousands by filing date
CELGENE CORP151020112RIGHT 12/31/2030490,000$1,455,000thousands by filing date
BIOLINERX LTD-SPONS ADR09071M106SPON250,000$528,000thousands by filing date
INSPIREMD INC45779A309COM1,250,000$400,000thousands by filing date
TRACON PHARMACEUTICALS INC89237H100COM12,172$171,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001546927-15-000149this filing2015-05-15acceptance time not in the bulk data set